Clay B. Siegall, Ph.D., is the president, C.E.O and Chairman of the Board of Seattle Genetics. The company was co-founded by Clay in 1998. He is a scientist by training with main emphasis focused on cancer therapies. After rigorous research, scientific innovation, development of drugs and passion to help patients, Dr. Siegall started Seattle genetics on these foundations.
He has played a pivotal role in guiding Seattle genetics in developing Antibody-drug Conjugates (ADC) that are used in treatment of cancer. Through his stewardship, he has also built on other antibodies including ADCENTRIES (brentuximab Vedotin). This was approved by the U.S Food and Drug Administration (FDA) in the year 2011.
From the news article in “Seattle Business Magazine”, it highly rates Seattle genetics to be the region’s dominant company. This immense success is thus a major concern of whether Seattle genetics may be a target of acquisition in the local industry.
One of the contributing factors of this success is its ability to connect therapy to the antibodies. These antibodies in turn provide a poisonous load inside the cancer cell and destroy it completely from inside. This strategy is in a position to catapult Seattle genetics to high heights.
Another contribution of this success is the company’s perseverance during the ups and downs that they face in this sector. Also, they decided not to decamp from Seattle genetics just like what Immunex did when it was acquired by Amgen. Seattle genetics is thus ranked to be one of the largest biotech in Washington. It has an estimated value of $10 billion and with over 900 employees.
The main strategy of Seattle is investing in research and marketing. It thus expects to acquire 200 extra employees every year. Clay Siegall’s ambition also lies in his desire to change his focus on drug development and embark in handling complexities involved in marketing newer drugs internationally. This desire is ignited when Siegall learns global marketing in Taxeda. To facilitate the company’s international marketing, Siegall opened an office in Switzerland.
Clay .B. Siegall, apart from being the C.E.O of Seattle’s Genetics, his professional career also centers in holding various positions. In year 2014, Clay Siegall together with Matthew Fust was appointed in the position of Board of Directors in Ultragenyx Pharmaceutical Inc. This followed after the resignation of Mr.Ben Auspitz. Their experience and expertise in this field is what led to these appointments.